Consent

This site uses third party services that need your consent.

The science of hair regeneration.

At Mallia Therapeutics, we redefine the future of hair regeneration. Our first goal is to provide a sustainable, science-based solution for people suffering from hair loss.

.

Our leadership team – pioneers in hair regeneration.

Science is in our DNA - and we are convinced that true innovations are based on a deep understanding of science. That is why we work with a passionate team of experts to navigate the journey from research to clinical application. We are determined to shape the future of hair regeneration with confidence, excellence and responsibility.

.

Prof. Dr Alexander Steinkasserer

Co-Founder & Managing Director
  • One of the leading international experts in the field of imune modulation via sCD83

  • More than 35 years of experience in molecular and cellular immunology as well as molecular biology, more thean 170 peer reviewed publications

  • Professor & Head of the Department of Immunomodulation at the University Hospital Erlangen

  • Industry experience at Novartis and Baxter.

.

Dr Stefan Strobl

Managing Director
  • More than 25 years of experience in the biotechnology industry; Managing Director of 4SC and BioNTech subsiduaries

  • Project management along the value chain: From hit ID to clinical phase I

  • Proficient in R&D processes: Pharmacology, PK, tox, CMC, compiling of regulatory documents, biomarker analysis, intellectual property

  • Extensive experience in immunology projects

Our achievements and milestones.

.

Research & discovery:

sCD83-derived MAL-856 molecule as a new therapy against hair loss, better wound healing as well as modulation of inflammatory and autoimmune diseases.
.

IP protection:

European patent granted in May 2025. Additional patent applications have been filed in several other countries including USA, Canada and Japan.
.

Company foundation:

June 2023
.

Current therapeutic focus:

Provide innovative therapies for people suffering from hair loss.
.

Pipeline and sustainability:

Clinical development of new therapeutics for wound healing, inflammatory skin disorders, as well as autoimmune diseases.

Stay informed.

Whether it concerns the latest research findings, clinical updates, publications or business news – our dedicated Therapeutics News section keeps you well informed.

Go to Therapeutics news
.

Copyright © 2025. Mallia Therapeutics.